Want to see IN:PPLPHARMA full AI Analyst Report?
PPLPHARMA Stock Chart & Stats
₹192.65
-₹4.80(-1.92%)
At close: 4:00 PM EST
₹192.65
-₹4.80(-1.92%)
Day’s Range― - ―
52-Week Range₹132.50 - ₹209.45
Previous CloseN/A
Volume1.66M
Average Volume (3M)264.14K
Market Cap
₹261.08B
Enterprise Value₹223.95K
Total Cash (Recent Filing)₹13.55B
Total Debt (Recent Filing)₹56.75B
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Nov 11, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend Yield0.07%
Share Statistics
EPS (TTM)-2.47
Shares Outstanding1,331,348,100
10 Day Avg. Volume501,791
30 Day Avg. Volume264,138
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.22
Price to Sales (P/S)2.04
P/FCF Ratio35.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.45
Revenue Forecast (FY)₹100.54B
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumSustained top-line expansion across several years provides structural leverage: larger scale supports higher utilization, bargaining power with suppliers/customers, and capacity to invest in CDMO and specialty product lines. This durable revenue base underpins long-term growth optionality despite margin swings.
Improved Cash GenerationMaterial improvement in operating cash flow and a return to positive free cash flow strengthens financial flexibility. Consistent cash generation supports reinvestment in manufacturing capacity, funds CDMO project ramp-ups and reduces near-term reliance on external financing for strategic spends.
Diversified Business ModelExposure across CDMO, complex generics and OTC creates multiple durable revenue streams and reduces single-market dependence. CDMO contracts offer high-value, repeatable work; branded OTC and hospital products provide margin diversification and cross-selling opportunities over the medium term.
Bears Say
Profitability VolatilityRecurring swings to net losses indicate earnings quality issues and reduce predictability of returns. Volatility can constrain reinvestment, complicate contracting with large pharma customers and limit sustained dividend or buyback policies, raising structural risk if negative episodes repeat.
Rising Debt & Inconsistent ROEMaterial increase in leverage and intermittent negative ROE weaken balance-sheet resilience. Higher fixed obligations reduce financial headroom for capex or acquisitions and amplify earnings pressure in downturns, while inconsistent returns suggest capital deployment has not reliably generated shareholder value.
Historic Cashflow InstabilityPrior multi-year negative free cash flow raises concern about sustainability of recent improvements. If working capital or project timings reverse, liquidity could tighten and the firm may need external financing for capex or CDMO ramp-ups, creating structural execution risk over the medium term.
Piramal Pharma Limited News
PPLPHARMA FAQ
What was Piramal Pharma Limited’s price range in the past 12 months?
Piramal Pharma Limited lowest stock price was ₹132.50 and its highest was ₹209.45 in the past 12 months.
What is Piramal Pharma Limited’s market cap?
Piramal Pharma Limited’s market cap is ₹261.08B.
When is Piramal Pharma Limited’s upcoming earnings report date?
Piramal Pharma Limited’s upcoming earnings report date is Nov 11, 2026 which is in 99 days.
How were Piramal Pharma Limited’s earnings last quarter?
Piramal Pharma Limited released its earnings results on Jul 29, 2026. The company reported -₹0.5 earnings per share for the quarter, beating the consensus estimate of -₹0.66 by ₹0.16.
Is Piramal Pharma Limited overvalued?
According to Wall Street analysts Piramal Pharma Limited’s price is currently Overvalued.
Does Piramal Pharma Limited pay dividends?
Piramal Pharma Limited pays a Notavailable dividend of ₹0.14 which represents an annual dividend yield of 0.07%. See more information on Piramal Pharma Limited dividends here
What is Piramal Pharma Limited’s EPS estimate?
Piramal Pharma Limited’s EPS estimate is -0.01.
How many shares outstanding does Piramal Pharma Limited have?
Piramal Pharma Limited has 1,331,348,100 shares outstanding.
What happened to Piramal Pharma Limited’s price movement after its last earnings report?
Piramal Pharma Limited reported an EPS of -₹0.5 in its last earnings report, beating expectations of -₹0.66. Following the earnings report the stock price went up 1.215%.
Which hedge fund is a major shareholder of Piramal Pharma Limited?
Currently, no hedge funds are holding shares in IN:PPLPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Jubilant Ingrevia Ltd.
―
Syngene International Ltd.
―